(Q40106465)

English

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines (English)

1 reference

Europe PubMed Central

17 September 2017

author name string

D W Rusnak

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

K J Alligood

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

R J Mullin

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

G M Spehar

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

C Arenas-Elliott

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

A-M Martin

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

Y Degenhardt

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

S K Rudolph

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

T F Haws

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

B L Hudson-Curtis

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

T M Gilmer

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

publication date

1 August 2007

1 reference

Europe PubMed Central

17 September 2017

Cell Proliferation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

40

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

580-594

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

FDA drug approval summary: erlotinib (Tarceva) tablets

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

Clinical implications of human papillomavirus in head and neck cancers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

New model of ErbB-2 over-expression in human mammary luminal epithelial cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

Oncogenic growth factor receptors: implications for signal transduction therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

HER-2/neu as a predictive marker of response to breast cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2007.00455.X

21 January 2018

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17635524

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17635524

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line Herceptin monotherapy in metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17635524

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17635524

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17635524

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

1 reference

https://pubmed.ncbi.nlm.nih.gov/17635524

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2184.2007.00455.X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6495710&resulttype=core&format=json

14 May 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40106465&oldid=1885379976"